Launching in today’s unpredictable market is a journey with new challenges around every corner.
While the oncology pipeline is rapidly growing, stringent competition and an evolving provider environment are putting intense pressure on manufacturers to build effective commercialization infrastructures and launch products at unprecedented speeds, which comes at a steep price. Prepping for launch and the first five years of commercialization costs $265M on average and can range anywhere from $150 to $450M.
As science works at warp speed to treat cancer patients, the traditional commercialization process is still too inefficient, costly and cumbersome – but there’s another option. Finally, the pharmaceutical industry is catching up to the oncology manufacturers who are innovating to extend survival, helping them streamline launch and maximize brand value to improve patient outcomes.
The 3 Pillars of Commercialization
While there are traditional, common pathways to commercialize, these options cause manufacturers to lose ownership in an investment that takes years – sometimes decades – to develop. Oncology manufacturers should not be forced to sacrifice their company value to make their life-changing product available to patients; nor should they have to invest more than $200MM over three years to commercialize on their own.
EVERSANA’s end-to-end, integrated model, EVERSANA COMPLETE Commercialization™, is uniquely designed to address challenges in the oncology pipeline with agility and data-driven solutions. With an infrastructure based on product and patient needs, COMPLETE Commercialization provides manufacturers the flexibility and expertise to customize their strategies and build functional service areas for a successful launch. Today’s oncology manufacturers need to leverage the “3 Pillars of COMPLETE Commercialization,” which include these key elements to a successful launch:
- A deep bench of industry experts
- An agile, fit-to-scale model that addresses the unique needs of each product
- All commercial services (e.g., patient services, field solutions, market access, etc.) under one roof
With one accountable commercialization partner to make decisions with, manufacturers can enable connectivity between services to manage costs, lower compliance and competitive risks and increase speed to launch in today’s complex market – and ultimately provide timely patient access. EVERSANA’s innovative model overcomes launch complexities and inefficient strategies to get therapies to cancer patients with increased speed, agility and momentum.